Advanced Solid Tumor
Conditions
Interventions
Group 1:JY025, 4mg/kg, intravenous infusion
Group 2:JY025, 8mg/kg, intravenous infusion
Group 3:JY025,12mg/kg, intravenous infusion
Group 4:JY025,16mg/kg, intravenous infusion
Group 5:JY025,20mg/kg, intravenous infusion
Group 6:JY025,24mg/kg, intravenous infusion
Group 7:JY025, paclitaxel, intravenous infusion
Group 8:JY025, Irinotecan, 5-Fluorouracil, Folinic Acid, intravenous infusion
Group 9:JY025, intravenous infusion, best supportive care
Sponsors
307th Hospital of Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The patient or his legal representative signs a written informed consent; 2. Aged 18-70 years; 3. Participants with histopathologically or cytologically diagnosed advanced solid tumors; 4. The ECOG score is 0-1; 5. The estimated survival time is greater than 12 weeks.
Exclusion criteria
Exclusion criteria: 1. Patients with other malignant tumors, excluding non-melanoma skin cancer, cervical carcinoma in situ, other noninvasive carcinoma, precancerous lesions in situ or non-recurrent early stage malignant tumors in the past 5 years 2. Has elective or planned surgery to be conducted during the trial; 3. LVEF is less than 50%; 4. Has a serious or non healing wound, ulcer, gastrointestinal perforation or bone fracture; 5. Has a known allergy to monoclonal antibodyor any other ingredient in JY025 Injection; 6. Pregnant or lactating women; 7. Has known alcohol or drug dependency; 8. Is not considered to be suitable for this study, in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MTD;Safety Evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic characterization;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactJianming Xu
307th Hospital of Chinese People's Liberation Army
Outcome results
None listed